UMIN ID: UMIN000018721
Registered date:21/08/2015
Pharmacokinetic, pharmacodynamic and biomarker study of phase I/II study of olaparib in combination with eribulin mesylate for patients with recurrent or metastatic triple-negative-type breast cancer
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Breast Cancer |
| Date of first enrollment | 2013/08/19 |
| Target sample size | 66 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Clinical efficacy and safety Pharmacokinetics Pharmacodynamics Biomarkers |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 18years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Patient considered irrelevant by attending physician for the study |
Related Information
| Primary Sponsor | National Cancer Center Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Ministry of Health, Labour and Welfare of Japan |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Akihiko Shimomura |
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo Japan |
| Telephone | 03-3542-2511 |
| ashimomu@ncc.go.jp | |
| Affiliation | National Cancer Center Hospital Breast and Medical Oncology |
| scientific contact | |
| Name | Kenji Tamura |
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo Japan |
| Telephone | 03-3542-2511 |
| ketamura@ncc.go.jp | |
| Affiliation | National Cancer Center Hospital Breast and Medical Oncology |